About The Study: Among adults age 60 years and older in 19 U.S. states, respiratory syncytial virus (RSV) vaccination was associated with a reduced likelihood of hospitalization with RSV compared with no vaccination. These findings expand upon prelicensure trial results in 2 ways. First, they provide evidence of vaccine protection against RSV-associated hospitalization, of which an estimated 60,000 to 160,000 occur annually among U.S. adults age 65 years and older. Second, they demonstrate protection in a population that more closely represents those at high risk of severe RSV disease, including adults age 75 years and older and those with immunocompromising conditions.
About The Study: Among adults age 60 years and older in 19 U.S. states, respiratory syncytial virus (RSV) vaccination was associated with a reduced likelihood of hospitalization with RSV compared with no vaccination. These findings expand upon prelicensure trial results in 2 ways. First, they provide evidence of vaccine protection against RSV-associated hospitalization, of which an estimated 60,000 to 160,000 occur annually among U.S. adults age 65 years and older. Second, they demonstrate protection in a population that more closely represents those at high risk of severe RSV disease, including adults age 75 years and older and those with immunocompromising conditions.
Corresponding Author: To contact the corresponding author, Diya Surie, MD, email dsurie@cdc.gov.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jama.2024.15775)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA
